pkn2 Antibody

What is PKN2 and why is it important in research?

PKN2 (Protein Kinase N2, also known as PRK2, PRKCL2) is a serine/threonine protein kinase with a molecular weight of approximately 112 kDa (calculated), though it typically appears at ~130-140 kDa on Western blots due to post-translational modifications . Its importance stems from its involvement in multiple signaling pathways affecting cell growth, migration, and tumor progression. Recent research indicates PKN2 plays a critical role in enhancing the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs) in esophageal cancer by mediating fatty acid oxidation (FAO) . As a regulatory kinase, PKN2 has become a focal point in cancer immunology research, making reliable antibody detection crucial for investigating its expression and function.

What species reactivity is available for commercial PKN2 antibodies?

PKN2 antibodies are available with confirmed reactivity to multiple species, primarily:

When selecting an antibody, consider that sequence homology between species is high for PKN2, but validation in your specific experimental system remains essential . For cross-species studies, antibodies raised against conserved epitopes (such as those targeting the N-terminal region, e.g., Asp18-Asn207 in human PKN2) offer greater utility .

What are the validated applications for PKN2 antibodies?

Current PKN2 antibodies have been validated across multiple applications with varying recommended dilutions:

For optimal results, antibody performance should be validated in your specific experimental system, as cellular context can significantly affect detection efficiency .

How should Western blot protocols be optimized for PKN2 detection?

For optimal PKN2 detection by Western blot, consider these methodological refinements:

• Sample preparation: Use reducing conditions with complete protease inhibitor cocktails to preserve protein integrity.

• Gel percentage: Use 8-10% SDS-PAGE gels to properly resolve the ~130-140 kDa PKN2 protein.

• Transfer conditions: PVDF membranes are recommended over nitrocellulose for better protein retention.

• Antibody concentration: Start with 1 μg/mL concentration for monoclonal antibodies (e.g., clone #509105) or 1:1000 dilution for polyclonal options.

• Detection systems: HRP-conjugated secondary antibodies with ECL systems provide sufficient sensitivity for most applications.

Experimentally validated positive controls include A431 human epithelial carcinoma, TF-1 erythroleukemic, and C2C12 mouse myoblast cell lines . When troubleshooting, note that PKN2 typically appears at a higher molecular weight (~130-140 kDa) than its calculated weight (112 kDa) due to post-translational modifications .

What are the critical factors for successful immunohistochemical detection of PKN2?

Successful IHC detection of PKN2 requires careful attention to several methodological parameters:

• Antigen retrieval: TE buffer at pH 9.0 is recommended, though citrate buffer at pH 6.0 can serve as an alternative . Heat-induced epitope retrieval methods generally yield better results than enzymatic approaches.

• Antibody concentration: Begin with 1:200-1:500 dilution and optimize based on signal-to-noise ratio.

• Incubation conditions: Overnight incubation at 4°C often provides better specificity than shorter incubations at room temperature.

• Positive control tissues: Human stomach tissue and human colon cancer tissue have been validated as positive controls .

• Background reduction: Use appropriate blocking sera (5% normal serum from secondary antibody species) and include a 15-minute peroxidase block if using HRP detection systems.

For multiplexing studies, sequential staining protocols with appropriate antibody stripping between rounds is recommended to avoid cross-reactivity issues.

How can PKN2 antibodies be used to investigate its role in immunosuppression?

To investigate PKN2's role in immunosuppression, particularly in the context of myeloid-derived suppressor cells (MDSCs), consider these methodological approaches:

• Co-culture systems: Establish PMN-MDSC and CD4+/CD8+ T cell co-cultures to assess PKN2's impact on T cell proliferation. Flow cytometry with CFSE-labeled T cells can quantify proliferation inhibition .

• Cytokine profiling: Measure secreted IL-2, IFN-γ, IL-10, and TGF-β levels in culture supernatants using ELISA to assess PKN2's impact on the immunosuppressive cytokine profile .

• ROS and Arg-1 assessment: Evaluate reactive oxygen species (ROS) generation and arginase-1 (Arg-1) expression, as PKN2 overexpression has been shown to enhance both in MDSCs .

• PKN2 manipulation: Use lentiviral systems for PKN2 overexpression or knockdown to assess functional consequences. Ensure validation of expression changes via Western blot using PKN2 antibodies .

• In vivo validation: Complement in vitro studies with animal models, assessing tumor infiltration by CD8+ T cells using flow cytometry or immunohistochemistry with appropriate markers .

This multi-parameter approach will provide a comprehensive understanding of PKN2's role in modulating immune responses in the tumor microenvironment.

How can PKN2 antibodies be used to study its role in fatty acid oxidation (FAO)?

To investigate PKN2's newly identified role in regulating fatty acid oxidation (FAO), implement these methodological approaches:

• Oxygen consumption rate (OCR) measurement: Use a Seahorse XFe96 Analyzer to quantify FAO-dependent OCR in PKN2-manipulated cells. Include etomoxir (18 μM) as an FAO inhibitor to confirm FAO-specific effects .

• CPT1B expression analysis: Employ PKN2 antibodies in co-immunoprecipitation studies to investigate PKN2's interaction with CPT1B, the key enzyme regulating FAO .

• Promoter activity assessment: Use dual luciferase reporter assays with CPT1B promoter constructs to evaluate PKN2's effect on transcriptional regulation. HEK293 cells have been successfully used for such analyses .

• ChIP-qPCR assays: Implement chromatin immunoprecipitation with PKN2 antibodies to assess direct or indirect binding to regulatory regions of FAO-related genes. Use 1% formaldehyde for cross-linking and DNA fragmentation to 200-1000 bp lengths .

• STAT3 phosphorylation: Investigate the PKN2-STAT3-CPT1B pathway using phospho-specific antibodies to detect STAT3 activation levels in relation to PKN2 expression .

These approaches provide a comprehensive toolset for elucidating PKN2's mechanistic role in FAO regulation, particularly in the context of immune cell metabolism.

What are best practices for studying PKN2 in patient-derived organoid models?

Patient-derived organoid (PDO) models offer unique opportunities to study PKN2 in physiologically relevant systems. Consider these methodological approaches:

• Co-culture systems: Establish co-cultures of patient-derived organoids with autologous immune cells to evaluate PKN2's impact on tumor-immune interactions .

• Immunofluorescence detection: For organoid studies, optimize immunofluorescence protocols with extended permeabilization (0.5% Triton X-100, 30 minutes) and antibody incubation times (overnight at 4°C) to ensure adequate penetration into 3D structures.

• Multiplexed imaging: Combine PKN2 antibody staining with markers for proliferation (Ki-67), cell death (cleaved caspase-3), and immune cell infiltration (CD8, CD4) to comprehensively assess PKN2's functional impact.

• Gene manipulation in organoids: When introducing PKN2 overexpression or knockdown constructs, validate expression changes using both Western blot and immunofluorescence to confirm uniform manipulation throughout the organoid structure.

• Growth assessment: Quantify organoid growth following PKN2 manipulation, particularly in the presence of immune cells, as PKN2-overexpressing MDSCs have been shown to promote organoid growth through immunosuppressive effects .

This integrated approach allows for studying PKN2 function in systems that better recapitulate human disease compared to conventional 2D cell culture.

How should researchers address inconsistent PKN2 antibody staining patterns?

When encountering variable or inconsistent PKN2 staining patterns, implement these systematic troubleshooting approaches:

• Antibody validation: Verify antibody specificity using positive control lysates from cells known to express PKN2 (A431, TF-1, C2C12, NIH-3T3, L6, or Rat-2 cell lines) .

• Sample preparation optimization:

  • For protein extraction, ensure complete lysis using RIPA buffer supplemented with protease and phosphatase inhibitors

  • For tissue sections, optimize fixation time (typically 24h in 10% neutral buffered formalin) and sectioning thickness (4-5 μm recommended)

• Signal amplification: For low-abundance detection, consider using biotinylated secondary antibodies with streptavidin-HRP systems or tyramide signal amplification.

• Reduction of background:

  • Implement additional blocking steps with 5% BSA and 0.1% Tween-20

  • Include multiple washing steps between antibody incubations

  • For tissues with high endogenous peroxidase, extend hydrogen peroxide blocking to 30 minutes

• Batch processing: Process all comparative samples simultaneously using identical reagents and incubation times to minimize technical variation.

Document all optimization steps methodically, as PKN2 expression can vary significantly between tissue types and experimental conditions.

What strategies can improve detection of phosphorylated PKN2?

Detection of phosphorylated PKN2 presents unique challenges requiring specific methodological considerations:

• Phosphatase inhibition: Include multiple phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) in lysis buffers to preserve phosphorylation status.

• Rapid sample processing: Minimize time between tissue/cell collection and protein extraction to prevent phosphorylation loss.

• Phospho-specific antibodies: When available, use antibodies specifically targeting PKN2 phosphorylation sites rather than relying on general PKN2 antibodies followed by phospho-serine/threonine detection.

• Phos-tag™ SDS-PAGE: Consider implementing Phos-tag™ acrylamide gels for improved separation of phosphorylated and non-phosphorylated PKN2 forms.

• Stimulation controls: Include positive controls of cells treated with known PKN2 activators (e.g., phorbol esters) to confirm phospho-detection capability.

• Dephosphorylation controls: Treat parallel samples with lambda phosphatase to confirm phospho-specificity of detected bands.

These approaches collectively increase the likelihood of reliable phospho-PKN2 detection, essential for studying its activation status in different cellular contexts.

How might PKN2 antibodies facilitate investigation of its role in cancer immunotherapy resistance?

The emerging role of PKN2 in modulating immune responses suggests several promising research applications for PKN2 antibodies in cancer immunotherapy:

• Biomarker development: Evaluate PKN2 expression in tumor biopsies before and during immunotherapy to determine if expression levels correlate with treatment resistance. Standardized IHC protocols (1:200-1:500 dilution) with digital pathology quantification can provide reproducible assessment .

• MDSC profiling: Use flow cytometry with intracellular PKN2 staining (0.40 μg per 10^6 cells) to characterize MDSC populations in patient peripheral blood and tumor tissues during immunotherapy .

• Pathway inhibition studies: Combine PKN2 antibodies with phospho-STAT3 detection to monitor the effects of pathway-specific inhibitors on immunosuppressive signaling cascades .

• Single-cell analysis: Implement PKN2 antibodies in mass cytometry or imaging mass cytometry workflows to characterize PKN2 expression heterogeneity within tumor immune microenvironments at single-cell resolution.

• Therapeutic targeting validation: Use PKN2 antibodies to confirm target engagement in preclinical studies of PKN2 inhibitors designed to overcome immunotherapy resistance by reducing MDSC immunosuppressive function .

These applications could significantly advance understanding of PKN2's role in immunotherapy resistance and potentially inform development of combination therapies targeting the PKN2-STAT3-CPT1B axis.

What experimental designs are recommended for investigating PKN2's role in different cancer types?

To systematically investigate PKN2's role across diverse cancer types, consider these experimental design recommendations:

This systematic approach will help elucidate whether PKN2's functions and therapeutic targeting potential vary across cancer types, potentially revealing context-specific intervention strategies.